• robertward-radiusRobert (Bob) Ward is President and Chief Executive Officer of Radius. He is a global pharmaceutical industry leader managing all stages of drug development, commercialization, and strategic dealmaking and partnerships across multiple therapeutic areas. Prior to joining Radius, Mr. Ward was Vice President for Strategy and External Alliances for the New Opportunities iMed of AstraZeneca (AZ), where he led search and evaluate activities in areas outside of AZ’s historical therapeutic focus, including orphan drugs and endocrinology. In addition, he served as Co-Chair of the Joint Development Committees in AZ’s drug development partnerships with Alcon and Galderma. After starting his career in the Molecular Biology discovery group at Genentech, Mr. Ward progressed through a series of management and executive roles with established biopharmaceutical companies including NPS Pharmaceuticals, Schering-Plough (Merck), and Bristol-Myers Squibb. Mr. Ward received a B.A. in Biology and a B.S. in Physiological Psychology, both from the University of California, Santa Barbara; an M.S. in Management from the New Jersey Institute of Technology; and an M.A. in Immunology from The Johns Hopkins University School of Medicine.

  • Nick HarveyNick Harvey is Senior Vice President and Chief Financial Officer of Radius. He has more than 15 years of experience in building and financing life sciences and technology companies. Prior to joining Radius, he served for four years as Managing Director of Shiprock Capital, a venture capital firm, where he was responsible for deal-sourcing, negotiating and closing transactions, and developing strategic plans for portfolio companies. Before that, Mr. Harvey served as CFO of a number of venture-backed companies over a 10-year period, including Transfusion Technologies and Transcend Therapeutics. At Transfusion, he helped to close a major distribution agreement with Zimmer and oversaw the company's acquisition by Haemonetics. Mr. Harvey holds an undergraduate degree in Economics and a law degree with first-class honors from the Australian National University, and an MBA from the Harvard Business School.

  • Alan HarrisDr. Harris is Chief Medical Officer of Radius. He has over 25 years of experience in clinical research and development. Dr. Harris carries expertise in endocrinology, metabolism, diabetes, oncology, gastroenterology, cardiovascular disease, allergic and respiratory diseases. He has played a central role in the approval process and clinical development of 17 peptides, small molecules, and biological pharmaceutical drugs, including Natpara® (rhPTH 1-84) and has conducted or overseen hundreds of clinical trials in over 30 countries. Dr. Harris was the Senior Vice President of R&D and the Chief Medical Officer of NPS Pharmaceuticals, Therapeutic Head of Worldwide Medical Endocrine Care for Pfizer. Dr. Harris worked for nine years at Schering Plough, in a number of positions related to scientific and medical affairs, including Vice President of Global Health Research and Outcomes. During his tenure at Novartis he headed the clinical development of a major therapeutic peptide breakthrough therapy, octreotide (Sandostatin®), the first long-acting somatostatin analog approved worldwide for the treatment of malignant gastrointestinal endocrine tumors and growth hormone-producing tumors. In 2012, Dr. Harris founded SomPharmaceuticals SA, where he currently serves as Chairman of the Board of Directors. Dr. Harris was an associate professor of medicine at the University of California, Los Angeles from 1992 to 1994 and has been an adjunct professor of medicine endocrinology at New York University since 2003. Dr. Harris received his medical degree from the Louis Pasteur Faculty of Medicine, University of Strasbourg, France, and his Ph.D. in endocrinology from Erasmus University, Rotterdam, The Netherlands. Dr. Harris is the founder and chairman of Sompharmaceuticals SA, a Swiss company focused on the discovery and development of new generation of somatostatin peptide analogues for the treatment of Growth Hormone producing brain tumors that cause acromegaly and malignant Neuroendocrine Tumors (NETs) including carcinoids. Dr. Harris earned his medical degree from the Louis Pasteur Faculty of Medicine, University of Strasbourg, France, and his Ph.D. in endocrinology from Erasmus University, Rotterdam, The Netherlands. Dr Harris has authored over 120 peer reviewed scientific papers.

  • Greg WilliamsDr. Williams is Chief Development Officer of Radius. He is a pharmaceutical industry and drug development veteran with more than 30 years of experience leading new product development, regulatory affairs, lifecycle management and commercialization for both small biotechnology and large pharmaceutical companies. Prior to joining Radius, Dr. Williams was Vice President of Regulatory Affairs, Global Product and Clinical Development, and Program Management with The Medicines Company, where he led the successful NDA and MAA filings of the IV antihypertensive drug Cleviprex®. Earlier positions include Vice President of Regulatory Affairs, Regulatory Compliance and Program Management for NPS Pharmaceuticals, where he led the successful MAA filing of the osteoporosis drug Preotact™. He has also held various management positions in clinical and drug product development for Yamanouchi Pharma America, Theraport Biosciences, GlaxoSmithKline Consumer Healthcare, and Parke-Davis Pharmaceutical. Dr. Williams has a Ph.D. in Biopharmaceutics from Rutgers University and an MBA from Cornell University.
  • Gary HattersleyDr. Hattersley is Chief Scientific Officer of Radius. He has more than 20 years of experience in musculoskeletal research and is the author of numerous scientific publications related to bone biology and physiology. Prior to joining Radius, Dr. Hattersley was a Senior Scientist at Millennium Pharmaceuticals with responsibility for the discovery and development of novel small-molecule agents for the treatment of osteoporosis and other metabolic bone diseases. Dr. Hattersley also held positions at Genetics Institute/Wyeth Research investigating the application of the bone morphogenetic proteins in bone and connective tissue repair and regeneration. Dr. Hattersley received a PhD in Experimental Pathology from St. George's Hospital Medical School in London.
  • Mark Durand is Chief Commercial Officer of Radius. He has nearly 28 years of pharmaceutical industry experience in a variety of leadership roles in drug development and commercialization across multiple therapeutic classes and the generics space. He has led and completed transactions ranging from company and product acquisitions and divestitures, partnership collaborations and compound in-licensing. Mr. Durand has most recently been an independent consultant advising emerging pharmaceutical firms and he serves on the Board of Sorrento Therapeutics where he is also the Chairman of the Audit Committee.

    Previously, Mr. Durand was Senior Vice President and CFO for Watson Pharmaceuticals (now Actavis) where he was responsible for financial operations as well as Business Development and Investor Relations. Prior to that, Mr. Durand was CFO and Senior Vice President Business Development for Teva Pharmaceuticals, North America. There he also played a principal role in licensing, acquisition and integration activities including with Ivax Pharmaceuticals. Prior to joining Teva, he spent 18 years with Bristol-Myers Squibb. During his tenure there, Mr. Durand held a number of executive positions in business development, commercial operations and finance, including Vice President Neuroscience/Global Brand Champion where he led the prelaunch development and planning for Abilify, the largest U.S drug in 2013.

    Mr. Durand received a B.S. in Zoology from Duke University, an M.S. in Biological Sciences from Dartmouth and an M.B.A. in Finance and Marketing from the University of Chicago. He has served on the board of directors of public and private health care companies including Ivax Diagnostics and Medical Information Management Systems, as well as non-profit organizations including The Dartmouth Alumni Council.